The Ozempic Effect on Snack Food Companies

The rise of GLP-1 agonists like Ozempic and Wegovy has moved beyond the pharmaceutical industry and is sending shockwaves through the grocery aisle. As millions of consumers adopt these appetite-suppressing medications, major food conglomerates are scrambling to adapt. They are reshaping their product portfolios to prioritize nutrient density and portion control over sheer volume.

The New Math of Calorie Consumption

For decades, the business model of snack food giants relied on volume. The goal was to sell more units of chips, cookies, and sodas. However, the widespread adoption of GLP-1 drugs is fundamentally altering the demand curve. These drugs work by mimicking a hormone that signals fullness to the brain, effectively turning off “food noise.”

Analysts at Morgan Stanley estimate that 24 million people in the U.S. could be taking these medications by 2035. That represents roughly 7% of the total population. More importantly, the data suggests that patients on these drugs cut their daily calorie intake by 20% to 30%.

This reduction is not evenly distributed across all food groups. The cuts come primarily from high-fat, high-sugar items—the bread and butter of companies like PepsiCo, Mondelez, and Hershey. In late 2023, Walmart U.S. CEO John Furner noted that the retailer was already seeing a “slight pullback” in the overall food basket for customers filling these prescriptions. They were buying less food and slightly fewer calories.

Nestlé Leads the "Companion Food" Charge

While some companies are taking a wait-and-see approach, Nestlé has been the most aggressive in pivoting its strategy. The company recognized that while GLP-1 users eat less, they still need to meet basic nutritional requirements. Because their appetite is suppressed, every bite they take must be more functional.

In response, Nestlé launched Vital Pursuit, a line of frozen food specifically targeted at GLP-1 users. This is a concrete example of portfolio reshaping. The line includes products like protein-packed pasta bowls, sandwich melts, and pizzas.

The key differentiators for Vital Pursuit include:

• Portion Control: Smaller serving sizes aligned with a reduced appetite.
• Nutrient Density: High protein and fiber content to prevent muscle loss and digestive issues common with the drugs.
• Fortification: Added iron, calcium, and Vitamin A to ensure users don’t become malnourished despite lower caloric intake.

By marketing these as “companion foods” to the drug regimen, Nestlé is attempting to capture a specific, high-value customer segment rather than fighting a losing battle for mass calorie consumption.

The Shift to Protein and "Better-For-You" Snacking

A major side effect of rapid weight loss on drugs like Ozempic is the loss of lean muscle mass alongside fat. This has created a massive opportunity for brands that specialize in protein.

General Mills and Danone are leaning heavily into their yogurt and protein bar segments. General Mills has highlighted its reduced-sugar yogurt options and meat snacks as growth areas. The logic is that even if a consumer skips a bag of Doritos, they might reach for a beef jerky stick or a Greek yogurt to keep their energy up.

Conagra Brands, the parent company of Slim Jim, acts on similar data. They are positioning their meat snacks not just as convenience foods, but as high-protein fuel for those managing their weight.

PepsiCo, which owns Frito-Lay, faces a steeper challenge but is pivoting its marketing. CEO Ramon Laguarta has stated that the impact on their business is currently negligible, yet the company is visibly pushing its “better-for-you” portfolio. This includes:

• PopCorners: Air-popped snacks with lower calorie counts.
• SunChips: Whole grain options.
• Baked Lays: Lower fat alternatives to traditional potato chips.
• Zero Sugar Beverages: PepsiCo continues to reformulate sodas to remove sugar, aligning with the dietary shifts of weight-conscious consumers.

Economic Impact and Investor Sentiment

The “Ozempic Effect” caused significant volatility in the stock market during late 2023. Investors panic-sold shares of major food companies, fearing that a permanently less hungry population would decimate profits. Stocks for companies like Krispy Kreme and Kellanova saw temporary dips as the market digested the potential long-term threat.

However, the industry response suggests a pivot rather than a collapse. Food giants are raising prices to offset lower volume and are acquiring smaller health-focused brands. The strategy is moving from “share of stomach” (volume) to “quality of calories” (premium pricing).

For example, if a consumer buys one premium $6 protein shake instead of two $2 bags of chips, the revenue for the food company may remain stable or even grow, provided they own the protein shake brand. This is why M&A (mergers and acquisitions) activity in the health and wellness food sector is expected to rise.

Looking Ahead: The Future of the Grocery Aisle

We are likely to see a bifurcation in the snack aisle. One section will remain the traditional high-sugar, high-salt snacks for the general population. The other section will be distinctly marketed toward “metabolic health.”

Expect to see packaging changes that highlight:

• “Satiety supporting” ingredients.
• Slow-digesting carbohydrates.
• Clear labeling of protein-to-calorie ratios.

The food giants are not going to stop selling snacks. They are simply going to change what constitutes a snack. The focus is shifting from hyper-palatable foods designed to make you eat more, to nutrient-dense foods designed to help you eat just enough.

Frequently Asked Questions

Q: Which specific drugs are driving these changes in the food industry? A: The primary drivers are GLP-1 receptor agonists. The most well-known brand names are Ozempic and Wegovy (semaglutide) and Mounjaro and Zepbound (tirzepatide).

Q: Has any company launched a brand specifically for Ozempic users? A: Yes. Nestlé launched a frozen food line called Vital Pursuit in 2024. It is explicitly designed to support the nutritional needs of people taking GLP-1 weight-loss medications.

Q: Why are protein snacks becoming more popular due to these drugs? A: Rapid weight loss often results in muscle loss. To counteract this, doctors recommend patients eat a high-protein diet. Consequently, food companies are pushing products like Greek yogurt, meat snacks, and protein shakes.

Q: Are snack food sales actually declining? A: While dollar sales remain high due to inflation and price increases, volume (the amount of food sold) has seen pressure in certain unhealthy categories. Walmart executives have confirmed seeing a slight reduction in basket size for customers on these medications.